GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 1, 2025.

By Dennis Thompson HealthDay Reporter

TUESDAY, April 1, 2025 -- The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.

The number of people without diabetes taking a GLP-1 drug more than tripled between 2018 and 2022 in the U.S., researchers reported March 31 in the Annals of Internal Medicine.

Spending on these drugs reached $5.8 billion in 2022, with average prices consistently exceeding $1,500 per prescription, results show.

“Despite this, adoption remained limited, as only 1 in 250 U.S. adults without diabetes used a GLP-1 (drug) in 2022,” wrote the research team led by Michelle Dowsey, an epidemiologist with the University of Melbourne in Australia.

GLP-1 drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

Initially approved to control diabetes, the drugs’ effectiveness at helping people lose weight led to their later approval for that purpose as well.

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions.

Results showed that among people without diabetes, GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% in 2022.

That doesn’t seem like a lot, amounting to an estimated 854,000 Americans without diabetes using GLP-1 drugs to lose weight in 2022, but the drugs are costly, and can run close to $1,000 or more a month, researchers found.

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

On average, the drugs cost $1,540 per prescription, but patients paid an average of just under $35 out-of-pocket for each prescription.

The study provides the first characterization of nationwide GLP-1 use and spending among individuals without diabetes “to guide ongoing debates about balancing the sustainability of health care spending against improving accessibility and affordability of GLP-1 medications going forward,” researchers concluded.

Sources

  • Annals of Internal Medicine, March 31, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-02 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords